Bioinductive Implant for Tennis Elbow
Trial Summary
What is the purpose of this trial?
The investigators are testing the efficacy of a new, FDA-approved bioinductive patch in lateral epicondylitis (tennis elbow) patients. A bioinductive patch is an implant that may foster tendon regrowth and healing following surgery. Patients will be randomize into one of two groups: control and investigational. Patients in the "control group" will receive the normal surgery for patients who do not respond to physical therapy, lifestyle changes, and anti-inflammatory treatment. Patients in the "experimental group" will receive the same surgical treatment, with the addition of the bioinductive patch. This patch will be implanted during surgery. Then, using a combination of ultrasound studies and other measures, the investigators will assess how well the patch works compared to surgery alone.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It might be best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the treatment Smith & Nephew Bioinductive Implant for tennis elbow?
Is the Bioinductive Implant safe for use in humans?
How does the Smith & Nephew Bioinductive Implant treatment for tennis elbow differ from other treatments?
The Smith & Nephew Bioinductive Implant is unique because it uses a bioinductive material to encourage the body's natural healing process, potentially offering a less invasive alternative to traditional surgical options like elbow replacement, which involves replacing joint surfaces with metal and plastic components.910111213
Research Team
Stephanie J Muh, MD
Principal Investigator
Henry Ford Health System
Eligibility Criteria
This trial is for individuals with tennis elbow that hasn't improved after physical therapy, lifestyle changes, and anti-inflammatory treatments. It's not open to those who've had previous surgery on the affected elbow.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo surgical treatment with or without the bioinductive patch implant
Follow-up
Participants are monitored for safety and effectiveness after treatment using ultrasound and other measures
Treatment Details
Interventions
- Smith & Nephew Bioinductive Implant (Bioinductive Implant)
Smith & Nephew Bioinductive Implant is already approved in Japan for the following indications:
- Management and protection of tendon injuries in which there has been no substantial loss of tendon tissue
Find a Clinic Near You
Who Is Running the Clinical Trial?
Henry Ford Health System
Lead Sponsor
Smith & Nephew, Inc.
Industry Sponsor
Dr. Maria Berkman
Smith & Nephew, Inc.
Chief Medical Officer since 2023
MD from Harvard Medical School
Dr. Deepak Nath
Smith & Nephew, Inc.
Chief Executive Officer since 2022
PhD in Theoretical Mechanics, University of California, Berkeley